Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03370887 · ClinicalTrials.gov registry record · Phase 2

AZD8601 Study in CABG Patients

A Phase 2 study of Heart Failure, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
11
Enrollment target
10
Study locations

NCT03370887: Completed Phase 2 study of Heart Failure, sponsored by AstraZeneca.

NCT03370887 is a Phase 2 study of Heart Failure that has completed, run by AstraZeneca. The registered enrollment target is 11 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03370887, a Phase 2 study of Heart Failure, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
11 participants
Enrollment target
10
Study locations

Study Summary

This is a randomized, double-blind, placebo-controlled, sequential design, multicentre study in patients with moderately impaired systolic function undergoing CABG surgery. Twenty four (24) patients scheduled for elective bypass surgery will be randomized (up to approximately 33 patients if replacements are needed). The objective is to investigate safety and tolerability of AZD8601 following epicardial injection in patients undergoing Coronary Artery Bypass Grafting (CABG) surgery with moderately impaired systolic function. At Visit 3 patients will receive either AZD8601 or placebo as epicardial injections and will then be followed up at 14 days (telephone visit) and 1, 3 and 6 months (on-site) post-surgery.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG AZD8601

Study Locations (10)

Other

  • Research Site - Kuopio
  • Research Site - Tampere
  • Research Site - Turku
  • Research Site - München
  • Research Site - München
  • Research Site - Amsterdam
  • Research Site - Groningen
  • Research Site - Gothenburg
  • Research Site - Uppsala

Connecticut

  • Research Site - New Haven

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2018-02-05
Est. Completion 2021-06-30
Phase Phase 2
AstraZeneca

1,285 total trials

What the finished NCT03370887 record still lists

NCT03370887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03370887 lists 10 locations in 2 states (Other, Connecticut).

Frequently Asked Questions

What is clinical trial NCT03370887 about?

NCT03370887 is a clinical study titled "AZD8601 Study in CABG Patients". This is a randomized, double-blind, placebo-controlled, sequential design, multicentre study in patients with moderately impaired systolic function undergoing CABG surgery. Twenty four (24) patients scheduled for elective bypass surgery will be randomized (up to approximately 33 patients if replacem...

What is the current status of trial NCT03370887?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-02-05. Estimated completion is 2021-06-30.

What conditions does trial NCT03370887 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT03370887?

The interventions under investigation include: Placebo (DRUG), AZD8601 (DRUG).

Who is sponsoring clinical trial NCT03370887?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03370887 being conducted?

This trial has 10 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03370887's enrollment target sits among peer trials

11 381st of 397 higher than 16 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03370887, the US trial registry maintained by the National Library of Medicine. NCT03370887 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.